宣布了！600200 终止上市！影响6万多股民

Core Viewpoint - *ST Suwu has received a decision from the Shanghai Stock Exchange to terminate its stock listing due to significant violations, including false disclosures in annual reports and financial misstatements [2][3][6]. Group 1: Termination of Listing - On December 1, *ST Suwu announced it received a decision from the Shanghai Stock Exchange regarding the termination of its stock listing [2][3]. - The stock will enter a delisting preparation period starting December 9, with the last trading day expected to be December 29, lasting for 15 trading days [5][7]. Group 2: Violations and Penalties - The China Securities Regulatory Commission (CSRC) issued an administrative penalty against *ST Suwu for three major violations: failure to disclose the actual controller, inflating revenue and profits in annual reports from 2020 to 2023, and not disclosing related party non-operating fund occupation [6]. - The penalties include a fine of 10 million yuan for the company and a total of 20.5 million yuan for the chairman and vice chairman [6]. Group 3: Company Profile - *ST Suwu is a comprehensive listed company with a core focus on pharmaceuticals, significant involvement in real estate, and investment activities [8]. - Prior to the suspension, *ST Suwu had achieved five consecutive trading limit increases, with a closing price of 1.24 yuan per share and a total market capitalization of 880 million yuan as of November 25 [8]. - As of September 30, the number of shareholders was 67,406, reflecting a decrease of 1.99% from the previous quarter [9].